AliveCor Launches Groundbreaking, AI-Powered Kardia 12L ECG System in India
The Pocket-Sized System Detects 35 Cardiac Determinations, Including Heart Attacks, Using a Reduced Leadset for Timely, Accurate Diagnosis of Heart Diseases.
AliveCor, the global leader in AI-powered cardiology, announced the launch of its groundbreaking Kardia 12L electrocardiogram (ECG) system in India. Exclusively designed for use by healthcare professionals, Kardia 12L is the world's first AI-powered, handheld 12-lead ECG system with a unique single-cable design that can detect life-threatening cardiac conditions, including heart attack, with a reduced leadset.
Kardia 12L, which has received Central Drugs Standard Control Organisation (CDSCO) approval for use in India, detects 35 cardiac determinations (14 arrhythmias and 21 morphologies). This includes serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia.
"Kardia 12L enables physicians to rapidly detect heart diseases across a wide range of healthcare settings, making this critical medical device more accessible than ever before," said Priya Abani, CEO of AliveCor. "More importantly, the launch of the Kardia 12L ECG system in India marks a big win for physicians and patients in the country, at a time when the healthcare system has never been more constrained, or more in need of the access and efficiency this type of solution provides."
India is projected to suffer an economic loss of approximately $2.17 trillion due to cardiovascular diseases (CVD) between 2012 and 2030. While conventional 12-lead ECG machines are considered gold-standard and effective, they are limited by their size and complexity, often confining them to traditional hospital settings. Given this immense challenge, it is critically important to leverage AI-powered solutions to make life-saving cardiac diagnostics more accessible and affordable.
“AliveCor's Kardia 12L ECG System was born from our vision to leverage AI and revolutionize traditional ECG screening," said Dr. David E. Albert, Founder and Chief Medical Officer of AliveCor. "We have compelling clinical evidence that our AI, paired with our device's reduced leadset, delivers results on par with the gold-standard ECG that are typically only available in hospital settings, democratizing access to potentially life-saving heart data."
First launched in the U.S., Kardia 12L has been met with widespread clinical acceptance, laying the groundwork for a successful global rollout. The pocket-sized system offers outstanding clinical efficiency and performance, assisting clinicians in rapid disease detection and enhancing patient experience.
"The launch of Kardia 12L marks a new era in cardiac diagnostics. In a country facing a rising burden of heart disease, this innovation reflects the future of healthcare—one that is portable, powerful, and built to empower clinicians at the point of care," said Anuj Seth, Managing Director of AliveCor India Pvt. Ltd. "This groundbreaking achievement underscores our unwavering commitment to providing medical-grade cardiac diagnostic capabilities to every patient in need, improving access to medical-grade care."
Kardia 12L is battery-operated, weighs just 135 grams and can fit in a physician's lab coat pocket, making it significantly smaller, more portable and more convenient than conventional 12-lead ECG machines. Its streamlined leadset also makes it less invasive for patients, who do not need to fully disrobe during a reading. The device requires minimal self-guided training and is simpler to use than standard 12-lead ECG machines.
Got a story that Healthcare Executive should dig into? Shoot it over to arunima.rajan@hosmac.com—no PR fluff, just solid leads.